India now has its first dengue vaccine in India after the Drug Controller General of India granted marketing approval to Takeda Biopharmaceuticals India’s QDENGA, marking a significant milestone in the country’s long-running fight against one of its most persistent mosquito-borne diseases. The QDENGA vaccine approval covers use in people aged between four and 60 years and is administered as a two-dose regimen, positioning it as a potentially important tool against a disease that has strained public health systems for decades.
The arrival of a dengue vaccine in India carries particular weight given the scale of the country’s disease burden. India accounts for nearly one-third of the global dengue burden, with millions of infections estimated each year. Official figures recorded 121,824 dengue cases and 131 deaths in 2025, though health experts believe the true number of infections is considerably higher, since many cases go unreported or undiagnosed. Surveillance data for 2026 has already shown a steady rise in infections, underscoring why the introduction of a dengue vaccine in India has been so keenly anticipated by public health officials.
DCGI Dengue Vaccine Approval Removes Screening Barrier
Unlike some earlier dengue vaccine candidates, QDENGA can be administered regardless of whether a person has previously been infected with the virus, a distinction that sets this DCGI dengue vaccine approval apart from prior efforts. This removes the need for pre-vaccination screening, a requirement that had complicated the rollout of earlier vaccines and limited their usefulness in dengue-endemic regions where prior infection status is often unknown. The absence of a screening requirement is expected to make QDENGA considerably easier to deploy at scale across India’s high-risk states.
QDENGA is a live-attenuated tetravalent vaccine engineered to protect against all four dengue virus serotypes. It is built on a weakened Dengue Serotype-2 virus as its genetic backbone, with components from the remaining three dengue virus serotypes incorporated to generate broad immune protection. The two doses are given three months apart through a subcutaneous injection, a schedule designed to maximise long-term protection against the virus in its various forms.
Takeda Dengue Vaccine Backed by Extensive Global Data
The Takeda dengue vaccine has already secured approval in 43 countries across Asia, Europe and Latin America and has received World Health Organization prequalification, confirming that it meets international standards for quality, safety and efficacy. More than 32 million doses have been distributed globally to date, with countries such as Brazil having already incorporated the Takeda dengue vaccine into their national immunisation programmes, giving Indian regulators a substantial body of real-world experience to draw on.
The DCGI’s decision rests on an extensive clinical evidence base generated through Takeda’s global development programme, which involved more than 28,000 participants across nineteen Phase I, II and III clinical trials. The pivotal Phase III TIDES trial, encompassing more than 20,000 participants across eight countries, recorded an overall efficacy of 80.2 per cent against laboratory-confirmed dengue one year after completion of the two-dose schedule. The same study found the vaccine reduced dengue-related hospitalisation by 90.4 per cent at eighteen months, while longer-term follow-up showed 84.1 per cent protection against hospitalisation even after four and a half years, with seven years of accumulated data pointing to sustained protection and a favourable safety profile against all four dengue virus serotypes.
Dengue Vaccine in India – India-Specific Trial Data and Safety Profile
The approval was further supported by a separate Phase III clinical trial conducted within India among participants aged four to sixty. That study found the vaccine to be safe, well tolerated and capable of producing a strong immune response across children, adolescents and adults, findings that carried particular weight for regulators assessing the vaccine’s suitability for the Indian population specifically. Most reported side effects have been mild and temporary, typically limited to pain or redness at the injection site, headache, muscle pain and fatigue lasting a few days.
Health experts describe the approval as an important addition to India’s broader dengue control strategy, particularly as rapid urbanisation, climate change and expanding mosquito habitats continue to drive transmission nationwide. They caution, however, that the arrival of a dengue vaccine in India will not by itself eliminate the disease. Continued mosquito control measures, robust disease surveillance, sustained public awareness campaigns and early diagnosis will all remain essential to reducing India’s overall dengue burden in the years ahead.
Published in SouthAsianDesk, July 21, 2026
Follow SouthAsianDesk on X, Instagram and Facebook for insights on business and current affairs from across South Asia.
